What top creators are saying about Biogen Inc.(BIIB)

Biotechnology company partnered with Sage Therapeutics on the drug Zerzovay.

3 AI-extracted insights from 3 sources — podcasts, YouTube channels, and X/Twitter accounts.

Creator sentiment — last 30 days

Based on 2 scored insights about Biogen Inc..

Bullish
avg +0.30
2 bullish0 neutral0 bearish

Top creators covering Biogen Inc. (BIIB)

The 3 sources with the most insights about Biogen Inc. on Kazuha.

Latest insights about Biogen Inc. (BIIB)

AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.

Friday, September 18, 2026

Bullish

Viewed as fairly valued to potentially undervalued relative to its broader pipeline and commercial progress with Alzheimer's treatment Leqembi.

Bullish

Viewed as trading around fair value with potential for modest upside if currently slightly undervalued by the market.

Saturday, November 1, 2025

Very Bullish

As a partner on the drug Zerzovay, the company benefits from a powerful, organic celebrity endorsement that could drive the new drug's adoption.

Discussed alongside Biogen Inc. (BIIB)

Other assets that creators frequently mention in the same content as Biogen Inc..

Frequently asked

Which podcasters and creators cover Biogen Inc. (BIIB) the most?

The most active sources covering Biogen Inc. (BIIB) on Kazuha are @theshkrelipill, The New York Times, @shkreliplanet. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.

How many insights about Biogen Inc. (BIIB) are on Kazuha?

Kazuha has indexed 3 AI-extracted insights about Biogen Inc. (BIIB) from 3 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.

What other assets do creators discuss alongside Biogen Inc. (BIIB)?

Creators covering Biogen Inc. (BIIB) most frequently also discuss QCLS, RVMD, RARE, SLS, NOK. See the "Discussed alongside" section above for full asset pages.